PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years

NCT01296178 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloblastic Leukemia

Interventions

DRUG: IDARUBICINE
DRUG: ARA-C

Sponsor

PETHEMA Foundation